Get started
Work

Preliminary Results of a Phase II Trial of Montelukast for the Treatment of Bronchiolitis Obliterans Syndrome After HSCT

Year: 2012
Type: article
Study design: Clinical Trial
Abstract: Bronchiolitis obliterans syndrome (BOS) after allogeneic HSCT is a deadly manifestation of cGVHD. Current treatments are inferior and yield transient responses with published overall survival of 44% at 2 years. Although the pathogenesis of BOS after HSCT is unknown, a similar disease, BOS after lung transplant is associated with elevated leukotriene levels. We present preliminary results from a prospective, open label, phase II trial testing the efficacy of montelukast, a leukotriene inhibitor, for the treatment of BOS after HSCT.
DOI: 10.1016/j.bbmt.2011.12.421
Authors: K.M. Williams, S.Z. Pavletic, F.T. Hakim, S.A. Mitchell, J.C. Gea-Banacloche, L. Comis, E.W. Cowen, K. Baird, J.H. Shelhamer, B.A.J. Blacklock-Schuver, D. Avila, A. Carpenter, A. Urban, T. Taylor, D. Zuchlinski, J. Baruffaldi, S. Lee, R.E. Gress
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W4251320934
FWCI:
Cites:
Cited by:
Related to: 10